关键词: font-size:medium, ">信迪利单抗；贝伐珠单抗；肺腺癌

Abstract: Objective：To study the clinical efficacy and safety of sindilizumab combined with bevacizumab in second-line treatment of advanced lung adenocarcinoma (LA). Methods：68 patients with advanced metastatic LA in our hospital (From October 2019 to December 2020) were selected and divided into control group (34cases) and observation group (34cases) according to different treatment regimens. Both groups were given conventional treatment, the control group was treated with cindilizumab, and the observation group was treated with cindilizumab combined with bevacizumab second-line treatment. Clinical efficacy, tumor marker levels [CEA,VEGF, CARBOHYDRATE antigen 125 (CA125)], scores of tumor quality of life Questionnaire (QLQ-C30), ability of daily living (ADL) score, and toxic and adverse reactions were compared between the two groups. Results：The objective remission rate in observation group was 44.12% higher than 29.41% in control group, and the disease control rate was 61.76% higher than 41.18% in control group (P＜0.05). After treatment, CEA, VEGF and CA125 levels in the observation group were lower than those in the control group (P<0.05). After treatment, the overall function and ADL score of the observation group were higher than those of the control group, but the score of specific symptoms was lower than that of the control group (P＜0.05). There was no significant difference in the incidence of toxicity and side effects between the two groups (P＜0.05). Conclusion：Sindelizumab combined with bevacizumab in the second-line treatment of patients with advanced metastatic LA has an accurate clinical efficacy, which can effectively improve the level of tumor markers, improve patients′ quality of life and self-care ability, with high safety.

Key words: Sindilizumab, Bevacizumab, Lung adenocarcinoma